Company Description
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States.
The company’s lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis.
It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases.
It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia.
Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.
| Country | United States |
| Founded | 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 6 |
| CEO | Michael Myers |
Contact Details
Address: 42127 Pleasant Forest Court Ashburn, Virginia 20148-7349 United States | |
| Phone | 703 980 4182 |
| Website | quoinpharma.com |
Stock Details
| Ticker Symbol | QNRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001671502 |
| CUSIP Number | 74907L409 |
| ISIN Number | US74907L4095 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Michael Myers Ph.D. | Co-Founder, Chief Executive Officer and Chairman |
| Denise Carter | Co-Founder, Chief Operating Officer and Director |
| Sally Lawlor | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 2, 2026 | DEF 14A | Other definitive proxy statements |
| Sep 25, 2026 | EFFECT | Notice of Effectiveness |
| Sep 25, 2026 | 424B3 | Prospectus |
| Sep 22, 2026 | PRE 14A | Other preliminary proxy statements |
| Sep 22, 2026 | 8-K | Current Report |
| Sep 18, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Sep 10, 2026 | D | Notice of Exempt Offering of Securities |
| Sep 10, 2026 | 8-K | Current Report |
| Aug 28, 2026 | 8-K | Current Report |
| Aug 20, 2026 | 8-K | Current Report |